Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/OGT_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/OGT_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/OGT_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/OGT_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/OGT_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003243419 | Prostate | Tumor | regulation of proteasomal ubiquitin-dependent protein catabolic process | 55/3246 | 134/18723 | 8.40e-11 | 5.27e-09 | 55 |
GO:000762315 | Prostate | Tumor | circadian rhythm | 75/3246 | 210/18723 | 1.09e-10 | 6.79e-09 | 75 |
GO:003292213 | Prostate | Tumor | circadian regulation of gene expression | 34/3246 | 68/18723 | 6.70e-10 | 3.39e-08 | 34 |
GO:004217718 | Prostate | Tumor | negative regulation of protein catabolic process | 49/3246 | 121/18723 | 1.53e-09 | 7.19e-08 | 49 |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000726514 | Prostate | Tumor | Ras protein signal transduction | 101/3246 | 337/18723 | 6.29e-09 | 2.44e-07 | 101 |
GO:000989518 | Prostate | Tumor | negative regulation of catabolic process | 96/3246 | 320/18723 | 1.40e-08 | 5.07e-07 | 96 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:190165315 | Prostate | Tumor | cellular response to peptide | 104/3246 | 359/18723 | 2.71e-08 | 8.90e-07 | 104 |
GO:004586119 | Prostate | Tumor | negative regulation of proteolysis | 102/3246 | 351/18723 | 3.09e-08 | 9.94e-07 | 102 |
GO:003133019 | Prostate | Tumor | negative regulation of cellular catabolic process | 81/3246 | 262/18723 | 4.42e-08 | 1.37e-06 | 81 |
GO:001657013 | Prostate | Tumor | histone modification | 126/3246 | 463/18723 | 5.51e-08 | 1.65e-06 | 126 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:000913216 | Prostate | Tumor | nucleoside diphosphate metabolic process | 46/3246 | 124/18723 | 1.15e-07 | 3.01e-06 | 46 |
GO:003166719 | Prostate | Tumor | response to nutrient levels | 127/3246 | 474/18723 | 1.27e-07 | 3.28e-06 | 127 |
GO:000918517 | Prostate | Tumor | ribonucleoside diphosphate metabolic process | 41/3246 | 106/18723 | 1.47e-07 | 3.72e-06 | 41 |
GO:190332119 | Prostate | Tumor | negative regulation of protein modification by small protein conjugation or removal | 38/3246 | 95/18723 | 1.49e-07 | 3.76e-06 | 38 |
GO:200005918 | Prostate | Tumor | negative regulation of ubiquitin-dependent protein catabolic process | 24/3246 | 48/18723 | 2.17e-07 | 5.26e-06 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OGT | SNV | Missense_Mutation | novel | c.1945N>C | p.Glu649Gln | p.E649Q | O15294 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
OGT | SNV | Missense_Mutation | novel | c.278C>T | p.Ser93Leu | p.S93L | O15294 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OGT | SNV | Missense_Mutation | rs267606503 | c.1042C>T | p.Arg348Cys | p.R348C | O15294 | protein_coding | deleterious(0.01) | benign(0.158) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OGT | SNV | Missense_Mutation | novel | c.1612C>A | p.Leu538Ile | p.L538I | O15294 | protein_coding | deleterious(0.03) | benign(0.08) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OGT | SNV | Missense_Mutation | rs778629433 | c.557N>T | p.Thr186Met | p.T186M | O15294 | protein_coding | tolerated(0.11) | probably_damaging(0.995) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
OGT | SNV | Missense_Mutation | rs200109331 | c.588N>G | p.Asn196Lys | p.N196K | O15294 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0RX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
OGT | SNV | Missense_Mutation | | c.1288N>A | p.Asp430Asn | p.D430N | O15294 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD |
OGT | SNV | Missense_Mutation | | c.1390N>A | p.Asp464Asn | p.D464N | O15294 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
OGT | SNV | Missense_Mutation | | c.2861N>T | p.Arg954Leu | p.R954L | O15294 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-LL-A6FP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
OGT | SNV | Missense_Mutation | novel | c.687C>G | p.Ile229Met | p.I229M | O15294 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |